New Horizon Health is the pioneer and market leader in China's cancer screening market focusing on early detection of high-incidence cancers. On February 18, 2021, New Horizon Health was successfully listed on the Stock Exchange of Hong Kong under the stock code of 6606.HK, becoming the "first cancer screening stock in China". New Horizon Health's two colorectal cancer screening products, ColoClear and Pupu Tube, as well as aH.pylori screening productUU Tube ,have been approved by the National Medical Products Administration (NMPA). ColoClear is currently the onlycancer screening product approved by theNMPA.UU Tube is currently the only self-conductedH.pylori screening product for home-use screening test approved in China. In addition, thecompany has three additional pipeline products for liver, cervical and nasopharyngeal cancer screening. Thecompany holds global rights in all its marketed and pipeline products.